贝达药业：控股子公司全面负责恩沙替尼项目在中国境外的开发和运作，目前暂未布局其他商品的营销推广

Core Viewpoint - The company, Betta Pharmaceuticals (300558.SZ), confirmed that its subsidiary, Xcovery Holdings, Inc., is currently focused solely on the overseas commercialization of Ensartinib and has not initiated marketing efforts for other products [2] Group 1 - The company is engaged in the overseas development and operation of the Ensartinib project through its subsidiary [2] - There are no current plans for the marketing and promotion of additional products by the subsidiary [2]